Business Context and Reporting Period
This Form 8-K Current Report was filed by DSS, Inc. on August 15, 2024. The filing addresses Item 5.02 regarding the departure of the Chief Executive Officer and the appointment of an Interim Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive leadership changes.
Material Changes
- CEO Departure: Frank D. Heuszel announced his resignation as Chief Executive Officer, effective at the close of business on August 23, 2024.
- Reason for Departure: The resignation does not reflect any disagreement with the Company regarding operations, policies, or practices.
- Leadership Appointment: The Board of Directors elected Jason Grady as the new Interim Chief Executive Officer, effective August 23, 2024.
Management Commentary and Risks
Interim CEO Profile: Jason Grady, 50, has served as Chief Operating Officer of DSS, Inc. since 2019. He concurrently holds leadership roles at DSS subsidiaries, including President of Premier Packaging Corporation, President and COO of DSS Wealth Management, and President and COO of BioLife Science, Inc. He brings over 25 years of experience in business expansion and executive leadership across packaging, pharmaceutical, and biomedical sectors.
Compensation and Relationships: There is no arrangement or understanding regarding Mr. Grady's election as Interim CEO. No family relationships exist between Mr. Grady and other directors or officers, and he is not a party to a related party transaction.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (August 23, 2024).
- Verify the absence of any undisclosed disputes between the departing CEO and the Board.
- Review the scope of Mr. Grady's concurrent roles to assess potential time allocation conflicts.
- Monitor future filings for the appointment of a permanent CEO and any associated compensation plans.